Neurodegenerative diseases and neuronal injuries continue to be an area rife with substantial unmet medical need. Targeting the underlying mechanisms of these diseases is an area of active research for effective therapeutic interventions, but extensive preclinical and clinical efforts have unfortunately resulted in limited success.
Magnolia Neurosciences Corporation, created to pursue technologies developed at The University of Texas MD Anderson Cancer Center’s Therapeutics Discovery Division and the Neurodegeneration Consortium (NDC), is a New York-based Accelerator Life Science Partner portfolio company. With its $31 million Series A financing announced in August of 2018, Magnolia Neurosciences aims to discover and develop proprietary, potent, and selective therapies for the prevention of neuronal cell death, thereby providing novel treatment options for patients suffering from neurodegeneration and related conditions.